Medexus Pharmaceuticals (TSE:MDP) Price Target Raised to C$6.25 at Ventum Financial

Medexus Pharmaceuticals (TSE:MDP) had its price objective lifted by equities research analysts at Ventum Financial from C$5.00 to C$6.25 in a research note issued to investors on Thursday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Ventum Financial’s price objective would suggest a potential upside of 57.43% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a report on Wednesday, January 8th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Finally, Stifel Nicolaus boosted their price objective on shares of Medexus Pharmaceuticals from C$4.50 to C$6.00 in a research note on Thursday. Two research analysts have rated the stock with a buy rating and five have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy” and a consensus target price of C$6.13.

Medexus Pharmaceuticals Stock Down 0.7 %

Shares of MDP traded down C$0.03 during trading on Thursday, reaching C$3.97. 122,000 shares of the company traded hands, compared to its average volume of 192,164. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The stock has a market cap of C$97.38 million, a PE ratio of 79.40 and a beta of 1.96. The stock has a 50-day simple moving average of C$3.37 and a 200-day simple moving average of C$2.76.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.